Vaccinex announces publication of Phase 2 SIGNAL HD study in Nature Medicine showing pepinemab slows cognitive decline

VACCINEX, INC.

Phase 2 SIGNAL HD study results published in Nature Medicine (Aug 8, 2022) and Journal of Neuroinflammation.
Pepinemab significantly improved cognition in early manifest HD patients (HD-CAB Index p=0.007).
Pepinemab reduced caudate atrophy (p=0.017) and brain metabolic decline in FDG-PET.
Treatment was well-tolerated with 5% treatment-emergent adverse events vs 9% placebo.
Phase 1b/2a study of pepinemab in Alzheimer's disease initiated (NCT04381468).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.